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Background: Suture hole bleeding from synthetic grafts presents a hemostatic chal-
lenge. The designs of many vascular sealants are not optimal (non-adherence to wet
surfaces, excessive swelling, inflexible). PreveLeak™ (formerly ArterX®) is a polyalde-
hyde–bovine serum albumin-based sealant whose efficacy, safety, and performance were
evaluated in this first-in-human study.
Materials and methods: A prospective, single-arm, multicenter study was performed
in patients undergoing open vascular reconstructions with prosthetic grafts. Sealant was
applied to the suture line after completion of the anastomosis. The primary endpoint was
the incidence of immediate sealing (without clinically significant bleeding) upon clamp
release. Secondary endpoints were time to sealing, safety, and assessment of product
performance.
Results: Fifty-six anastomoses were performed in 32 patients. Grafts were Dacron (66%
of sites), polytetrafluoroethylene (PTFE; 32%), or both Dacron and PTFE (2%). The femoral
artery was the most common site of anastomosis (41% of sites). Immediate sealing
after clamp release was achieved at all anastomoses (100%); 93% had no bleeding and
7% had oozing. No rebleeding occurred during 10min of observation. The three most
common adverse events were graft or bypass occlusion (n=5 patients), infection (n=4),
and seroma (n=3); none were device related. The sealant was considered easy to apply,
quickly forming a soft gel, and adhering to tissue and grafts.
Conclusion: PreveLeak effectively sealed anastomotic suture lines during vascular
reconstruction procedures and was considered easy to use. Adverse events were
consistent with those commonly observed in patients undergoing surgical procedures.
These results provided the support for conducting a larger controlled clinical trial.
Keywords: surgical sealant, hemostasis, vascular surgery, safety, efficacy evaluation, albumin, polyaldehyde
Introduction
Anastomotic suture line bleeding with prosthetic grafts during vascular surgical procedures can
result in blood loss and potential need for reoperation (1, 2). One hemostatic challenge encountered
in patients undergoing vascular procedures is the use of synthetic graft materials [e.g., Dacron or
polytetrafluoroethylene (PTFE)], which eliminates the use of electrocautery as a technique to achieve
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hemostasis with suture holes. Hemostasis can also be affected by
use of medications commonly administered before or during sur-
gical procedures, including heparin, warfarin, antiplatelet agents
(e.g., clopidogrel), and novel oral anticoagulants (NOACs, i.e., fac-
tor Xa and direct thrombin inhibitors). The anticoagulant effects
of warfarin and heparin can be reversed by administration of vita-
min K and protamine sulfate, respectively; however, no treatment
is available to reverse the antiplatelet effects of clopidogrel or to
reverse the inhibition of factor Xa or thrombin with NOACs (3,
4). The performance of vascular surgical procedures in patients at
risk for bleeding of brisk intensity has led to an increased need for
robust methods for preventing suture line bleeding (5).
Four classes of surgical sealants are approved for use as adjunc-
tive therapywith sutures or staples during vascular procedures (6).
These products seal suture holes between the implanted prosthetic
vascular graft or patch and the patient’s native vessel either by
chemically binding to host tissue (three classes) or clot formation
(one class). The four classes of sealants include cyanoacrylates,
polyethylene glycols, mixtures of bovine serum albumin (BSA)
and glutaraldehyde or polyaldehyde, and fibrin sealants. Although
each class of sealant provides sealing, they differ in the characteris-
tics that can limit their use; for example, the cyanoacrylate sealant
(Omnex® Surgical Sealant; Ethicon, Inc.) will only adhere to dry
surfaces (6) and the polyethylene glycol hydrogel sealant (Coseal®
Surgical Sealant; Baxter Healthcare Corp.) can swell fourfold after
application (7). Fibrin sealants differ from the other three classes
of sealants in that they are also hemostatic agents. Tisseel™ (Baxter
Healthcare Corp.) and Evicel® (Ethicon, Inc.) contain human
plasma-derived fibrinogen and carry a risk of transmitting infec-
tious agents, a risk of air or gas embolism if administered with
pressurized gas (8, 9), andmay adhere differently to synthetic graft
material compared to native vessel in the absence of blood (10).
There are two members of the BSA and glutaralde-
hyde/polyaldehyde class of sealants: BioGlue Surgical Adhesive
(CryoLife, Inc.) and PreveLeak Surgical Sealant (formerly ArterX
Surgical Sealant; The Medicines Company). Both contain BSA
sourced from cattle certified as free of bovine spongiform
encephalitis (but still have the potential risk of transmitting other
infectious agents) and both are supplied in double-barrel syringes
with mixing tips (11, 12). When BSA is exposed to glutaraldehyde
in BioGlue, or to polyaldehyde in PreveLeak, the lysine residues
in the BSA are crosslinked with extracellular proteins and form a
mechanical seal, which is independent of the coagulation system
(13, 14).
The characteristics of PreveLeak, gelling within 10–15 s, flexi-
bility, swelling <10%, and adherence to a dry field or one where
blood and blood components are present (15), suggested that it
would be a useful surgical sealant for anastomotic suture line
bleeding. In the first-in-human trial described herein, the safety
and suture line sealing of PreveLeak were assessed after applica-
tion to anastomotic sites in patients undergoing vascular surgical
procedures.
Methods
Study Design
This prospective, single-arm, multicenter, first-in-human study
evaluated prophylactic sealing of suture lines at the anastomosis
between native vessels and synthetic vascular grafts using
PreveLeak, and was conducted at three German study sites
(June–November 2007). The primary objective of this study was
to evaluate the safety and performance of PreveLeak in achieving
sealing at suture lines between native and synthetic vascular grafts
used in the open surgical repair of large vessels, peripheral arterial
bypass, or arteriovenous (AV) graft formation for hemodialysis
access.
Within 7 days before the vascular surgical procedure, a screen-
ing visit was conducted to obtain pertinent medical history and
evaluate patient eligibility. A complete blood count (CBC) and
platelet count were obtained and current medication use was
documented [also performed on the operative day (day 1) and
post-procedure through discharge from the hospital]. On day 1,
patients underwent open vascular reconstructions with prosthetic
materials (PFTE or Dacron) according to standard practices. The
use of perioperative, intraoperative, and postoperative anticoag-
ulation was dependent on the Investigator’s discretion and not
specified by the study protocol. PreveLeakwas stored at 2–8°C and
applied prophylactically (up to 4mL) to the suture line after com-
pletion of the anastomosis or patch, but prior to the restoration of
arterial flow. Approximately 2min after application, arterial flow
was restored by removing the clamps and observation of sealing
was documented immediately following restoration of flow and
1, 3, 5, and 10min later (timed with a calibrated stop watch).
Bleeding was classified into one of four categories: no bleeding,
oozing, fast flow, or spurting. Each patient was treated at one
to three suture lines depending upon whether the patient was
receiving a graft or patch and the number of anastomoses or
suture lines. Product handling and performance were assessed
using a questionnaire. Adverse events and medication use were
also assessed at follow-up evaluations, 6 weeks and 3months after
the surgical procedure.
The Freiburg Central Ethics Committee gave national approval
for the study and each site received supplementary approval from
their hospital based or a surgical society ethics committee before
proceeding (clintrials.gov IDNumber: NCT02476318). The study
was designed to be in compliance with guidelines on the clinical
investigation of medical devices for human subjects (MEDDEV
2.7.1 and EN ISO 14155-1 and 2; 2003) and to adhere to the
ethical principles set forth by the Declaration of Helsinki. Sites
were to comply with applicable principles of Good Clinical Prac-
tice and all patients or their authorized representative provided
written informed consent before any study-specific procedures
were conducted.
Endpoints
The primary endpoint was the proportion of patients achieving
immediate suture line sealing on clamp removal, as evidenced
by a lack of clinically significant bleeding. A minimum of 50%
of the anastomoses were expected to be sealed immediately. The
secondary endpoint was time to sealing, measured immediately
after clamp removal and 1, 3, 5, and 10min later. A minimum of
80% of the anastomoses were expected to be sealed 10min after
clamp removal. Safety was assessed by recording adverse events
over the course of the study. User perception of the performance
of the productwas assessed by a questionnaire that asked about the
amount of material available for application, the delivery system
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performance, the material adhesive quality and gel rate, the ease
of use, and overall satisfaction with the product. There were four
possible responses for each of the six questions (excellent, good,
fair, or poor).
Patients
Adult patients were eligible if they were scheduled for surgical
placement of a prosthetic graft for large vessel repair, arterial
reconstruction, or AV graft formation for hemodialysis access;
had no child bearing potential or a negative serum or urine preg-
nancy test within 7 days before the procedure; and were willing
and able to be contacted for 6weeks of follow-up. Exclusion
criteria included known hypersensitivity, contraindication, or
allergic reaction to heparin, bovine, shellfish, or seafood products;
history of bleeding diathesis or coagulopathy; refusal to receive
blood transfusions; or concurrent enrollment in another clinical
trial.
Statistics
A sample size of 30–60 patients was considered appropriate based
on the study objectives. The decision to stop patient enrollment
was made after 30 patients completed the study as the observed
immediate sealing rate exceeded the 50% success criterion estab-
lished a priori. Two additional patients were enrolled after the
decision to stop enrollment wasmade but prior to communicating
the decision to Investigators.
No statistical comparisons were planned or performed. Results
are presented with descriptive statistics, with analyses performed
by an independent statistician (Willes Consulting Group, Encini-
tas, CA, USA). Adverse events are summarized by the verbatim
terms that the Investigators used to describe them.
Results
A total of 32 patientswere enrolled.Most patientsweremale (81%)
and median (range) age was 64.5 (46–86) years (Table 1). The
32 patients were treated with PreveLeak at 56 different suture
sites while undergoing bypass graft (69% of patients), arteri-
otomy (25%), or AV graft formation for hemodialysis access
(6%). The grafts were Dacron (66% of sites) or PTFE (32%),
with 1 site (2%) including overlapping Dacron and PTFE grafts.
The femoral artery was the most common (23) of the 53
recorded suture sites, with aortic (10), iliac (7), popliteal (4),
tibial (4), carotid (2), brachial (2), and subclavian (1) arteries also
utilized.
Efficacy and Performance of the Sealant
The primary endpoint, achieving immediate sealing without clin-
ically significant bleeding upon the release of clamps and the
restoration of blood flow, was met at 100% (n= 56) of the suture
sites (Table 2), with 93% of the sites (n= 52) having “no bleeding”
after clamp release and 7% of the sites (n= 4) having “oozing.”
The effect was durable, with “no bleeding” reported for 98% of
the sites (n= 55) at 10min and “oozing” reported at 2% of the
sites (n= 1). The effects of the sealant on the two different kinds of
graft materials were comparable (Table 3). The time to achieving
sealing without clinically significant bleeding (“no bleeding” or
TABLE 1 | Patient demographic and surgical characteristics.
Patients (N=32) Suture sites (N= 56)a
Mean (SD) age, years 66 (10:1) –
Median (range) age, years 64:5 (46; 86) –
Gender, n (%)
Male 26 (81) –
Female 6 (19) –
Surgical procedures, n (%)
Bypass graft 22 (69) 46 (82)
Arteriotomy 8 (25) 8 (14)
AV access graft 2 (6) 2 (4)
Graft material, n (%)
Dacron 22 (69) 37 (66)
PTFE 9 (28) 18 (32)
Dacron and PTFEb 1 (3) 1 (2)
aOne patient underwent two different procedures approximately 1week apart and
represented 4 of the 56 sites treated.
bDuring an arteriotomy sealing procedure in one patient, the new PTFE patch partially
overlapped an existing Dacron patch. PreveLeak was applied to both patches.
AV, arteriovenous; PTFE, polytetrafluoroethylene; SD, standard deviation.
“oozing”) was considered immediate for all types of procedures
and all graft materials (secondary endpoint). The investigators
considered the ease of preparing PreveLeak, the performance of
the delivery system, the gel rate, and the adhesiveness of PreveLeak
“good” or “excellent” for the procedures performed in 30 of 32
patients.
Safety
A total of 30 adverse events were reported by 22 of the 32
patients up to 90 days after treatment. The events were con-
sidered by the Investigators as not related (investigator assess-
ment of definitely or unlikely treatment-related) to treatment
with PreveLeak. The most commonly reported events were graft
or bypass occlusion (n= 5 patients), infection (n= 4), seroma
(n= 3), aneurysm (n= 2), lymphedema (n= 2), and peripheral
artery disease (n= 2). Other events were reported for only one
patient each. One severe event was reported (abdominal hernia
with ileus); the other events weremild (n= 13 events) ormoderate
(n= 16) in severity.
Discussion
Any sealant used prophylactically for the prevention of suture
hole bleeding during vascular reconstructive surgery with pros-
thetic grafts should be effective and fast acting to minimize blood
loss and the potential need for blood transfusion and associ-
ated costs. The results from this study demonstrated that Prev-
eLeak immediately sealed 100% of anastomotic sites in patients
undergoing vascular surgical procedures, with no adverse events
that could be attributed to the sealant. The sealing effect of
PreveLeak was durable, as 100% of application sites remained
sealed at 10min. This sealing effect occurred independently of
a patient’s coagulation cascade, was observed across a range of
procedures that involved anastomoses between native vessels and
Dacron or PTFE grafts, and the investigators considered Preve-
Leak easy to use. The most commonly observed adverse events
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TABLE 2 | PreveLeak performance by type of surgical procedure.
n (%) of sites
Bypass graft
(N=46)
Arteriotomy
(N=8)
AV access graft
(N= 2)
Any procedure
(N=56)
Bleedinga at 0min
“No bleeding” 43 (93) 7 (88) 2 (100) 52 (93)
“Oozing” 3 (7) 1 (13) 0 (0) 4 (7)
“No bleeding” or “oozing” 46 (100) 8 (100) 2 (100) 56 (100)
Bleedinga at 10min
“No bleeding” 45 (98) 8 (100) 2 (100) 55 (98)
“Oozing” 1 (2) 8 (100) 2 (100) 1 (2)
“No bleeding” or “oozing” 46 (100) 8 (100) 2 (100) 56 (100)
aBleeding was categorized as no bleeding, oozing, fast flow, or spurting.
AV, arteriovenous.
TABLE 3 | PreveLeak performance by type of graft material.
n (%) of sites
Dacron
(N=38b)
PTFE
(N= 19b)
Any material
(N=57b)
Bleedinga at 0min
“No bleeding” 34 (89) 19 (100) 53 (93)
“Oozing” 4 (11) 0 (0) 4 (7)
“No bleeding” or “oozing” 38 (100) 19 (100) 57 (100)
Bleedinga at 10min
“No bleeding” 37 (97) 19 (100) 56 (98)
“Oozing” 1 (3) 0 (0) 1 (2)
“No bleeding” or “oozing” 38 (100) 19 (100) 57 (100)
aBleeding was categorized as no bleeding, oozing, fast flow, or spurting.
bDuring an arteriotomy sealing procedure in one patient, the new PTFE patch partially
overlapped an existing Dacron patch. PreveLeak was applied to both patches, which are
counted separately in this table.
PTFE, polytetrafluoroethylene.
were consistent with those often seen in patients undergoing
surgical procedures or with the specific types of procedures being
performed.
Time to sealing is a widely used assessment tool in clini-
cal studies of surgical sealants, although comparisons of results
between studies must be interpreted with caution due to dif-
ferences in study design and/or patient populations studied. A
study of Omnex showed that it immediately sealed 55% of anas-
tomoses with synthetic grafts in femoral-popliteal bypass pro-
cedures and AV graft formation for hemodialysis access (16),
while in another study, immediate sealing was achieved in 71%
of patients undergoing vascular constructive surgery using PTFE
grafts (17). In patients undergoing similar types of surgical pro-
cedures, Coseal achieved immediate sealing in 47% of anasto-
motic sites (18). Application of BioGlue resulted in immediate
sealing of 61% of anastomotic sites in patients undergoing car-
diac or aortic reconstructive procedures or peripheral arterial
bypass (19).
PreveLeak is composed of BSA and a polyaldehyde crosslinker.
Additional components of PreveLeak include chitosan chlo-
ride, which enables the sealant to adhere to surfaces that
are dry or where blood and blood components are present;
sodium hyaluronate, which gives the sealant high-burst strength
(>500mmHg) and an elastic modulus similar to that of
healthy human aorta; and sodium carboxymethyl cellulose, which
increases the viscosity of the polyaldehyde and facilitates mix-
ing. During application, the BSA and polyaldehyde are mixed
in a self-mixing syringe tip. The mixture polymerizes quickly
and adheres to the application surface, which minimizes the
potential for leakage through suture holes and for emboliza-
tion (20). The BSA–polyaldehyde elastic, biocompatible gel forms
stable crosslinks between the primary and secondary amino
groups of the albumin molecules and the primary and sec-
ondary amino groups of the proteins on the surface at the
application site (21) and mechanically adheres to synthetic
grafts.
Reduced local toxicity is an advantage of the use of polyalde-
hyde over glutaraldehyde as a crosslinker because leaching of glu-
taraldehyde from cured BioGlue has been shown to be cytotoxic
and inflammatory in vitro and in vivo (22). This inflammation
may contribute to the development of pseudoaneurysm (23). In
non-clinical studies, PreveLeak, which contains polyaldehyde, has
been shown to be largely bioresorbed from the site of application
by 12months and was not cytotoxic in animal or clinical stud-
ies, although some cytotoxicity of extracts made from PreveLeak
was observed in cell culture-based laboratory assays at concen-
trations higher than those likely to be encountered clinically
(12, 15).
PreveLeak was designed to be compliant with the human aorta.
PreveLeak’s elastic modulus of 599 kPa (data on file), a mea-
sure of its stiffness, is comparable to that reported for human
aorta (455 kPa) (24). In contrast, BioGlue has a modulus value
of 3,122 kPa, which is greater than that of human aorta (24).
The modulus of BioGlue is also substantially greater than that
of Dacron (1,100 kPa when measured circumferentially). Thus,
polymerized BioGlue can contribute to complications at the anas-
tomotic site, including stricture, because it is stiffer than both the
native vessel and Dacron graft (25).
The primary limitation of the clinical study described herein
was the single-arm, open-label design. The Investigator apply-
ing PreveLeak was also responsible for determining the time to
sealing. Potential intra- and inter-observer variability were min-
imized by standardizing the assessment of time to sealing across
investigative sites, and potential bias was reduced by employing
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independent personnel who source-verified and analyzed the
data.
PreveLeak was effective in achieving rapid sealing after pro-
phylactic application in prosthetic arterial reconstruction. It was
well tolerated, with no adverse events considered device related.
The sealant was easy to apply, remaining soft and flexible and
firmly adherent to the application site. These results provided the
support for conducting a larger controlled clinical trial, in which
the performance and safety of the sealant could be more fully
evaluated.
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